EWTXEWTXHealthcare · Biotechnology

EWTX Stock Forecast: Edgewise Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 17 Nov 2026
$42
−3.75% on the day

The 13 Wall Street analysts covering Edgewise Therapeutics, Inc. hold a median 12-month price target of $54 — +27.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 69 of 100 as at 16 Nov 2026 — in the upper half.

Market cap
$4.8B
Ticker Nerd rank
69/ 100
Median analyst target
$54
Analysts covering
13
Revenue$0.0
Operating income−$61.9M
Net income−$57.3M
Free cash flow−$42.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−9.6%
1M
+13.0%
YTD
+69.4%
1Y
+88.9%
From 52W high
−13.7%
From 52W low
+100.8%
$21
$49
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

EWTX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Edgewise Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 16 Nov 2026
69/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
92
Value
85
Quality
78
Revisions
67
Growth
58
Issuance
42
Volatility
38
Accruals
30
Size
23

Momentum (92): The shares have been drifting up relative to others.

Accruals (30): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (23): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

EWTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on EWTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$40$60$80Jan 26Apr 26Jul 26Oct 26EWTXHigh $85Median $54Low $36

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says13 analysts
12 Buy1 Hold0 Sell
Low $36Median $54High $85

The green dot is the last close — the median target sits +27.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
5 Nov 2026WedbushMaintainsOutperform$53 → $51
16 Oct 2026William BlairInitiatesOutperform—
16 Oct 2026William BlairInitiatesOutperform—
21 Sept 2026HC Wainwright & Co.MaintainsBuy—
21 Sept 2026HC Wainwright & Co.MaintainsBuy$45 → $57
20 Aug 2026JP MorganMaintainsOverweight$53 → $60
20 Aug 2026JP MorganMaintainsOverweight—
11 Aug 2026Goldman SachsMaintainsNeutral$32 → $36
11 Aug 2026Goldman SachsMaintainsNeutral—
20 July 2026Evercore ISI GroupMaintainsOutperform$45 → $55
20 July 2026Evercore ISI GroupMaintainsOutperform—
9 July 2026OppenheimerInitiatesOutperform$51
9 July 2026OppenheimerInitiatesOutperform—
6 July 2026GuggenheimMaintainsBuy$41 → $51
6 July 2026GuggenheimMaintainsBuy—
17 June 2026Goldman SachsMaintainsNeutral—
17 June 2026RBC CapitalMaintainsOutperform—
16 June 2026HC Wainwright & Co.ReiteratesBuy—
2 June 2026HC Wainwright & Co.MaintainsBuy—
2 June 2026RBC CapitalMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

EWTX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

EWTX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 17 Nov 2026, Edgewise Therapeutics, Inc. returned +88.9% against +11.2% for the S&P 500, dividends included.

EWTX vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200Jan 26Apr 26Jul 26Oct 26EWTXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

EWTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
+449.1%
Analysts raising
0
Analysts cutting
0
Fundamentals

Edgewise Therapeutics, Inc. (EWTX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
5.2×

Cheaper than 65% of US stocks

Price / sales
—
Price / book
2.9×

Cheaper than 29% of US stocks

EV / EBITDA
−14.1×

Cheaper than 89% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 33% of US stocks

Net margin
0.0%

Higher than 29% of US stocks

Returns & dividend
Return on equity
92.1%

Higher than 96% of US stocks

Return on assets
−11.5%

Higher than 25% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Edgewise Therapeutics, Inc. (EWTX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Edgewise Therapeutics, Inc. has a market value of $4.8B and an enterprise value of $3.0B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$197.2M.

  • Diluted earnings per share, trailing twelve months: −$1.85.

  • Free cash flow in the twelve months to 30 June 2026: −$158.8M.

  • Shares outstanding: 107.8M.

  • Trailing P/E: 5.2×; forward P/E: −23.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Edgewise Therapeutics, Inc. employs 133 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 17 Nov 2026

Data provided by Twelve Data

Peers

EWTX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
EWTXEdgewise Therapeutics, Inc.$4.8B69
TVTXTravere Therapeutics, Inc.$4.7B77
COGTCogent Biosciences, Inc.$4.7B33
IONSIonis Pharmaceuticals, Inc.$4.7B41
DNTHDianthus Therapeutics, Inc.$4.9B77
PTCTPTC Therapeutics, Inc.$5.1B64
ERASErasca, Inc.$5.2B48

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Edgewise Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest EWTX news & analysis

Edgewise Therapeutics to Participate in Upcoming Investor Conferences

PRNewsWire · 9 Nov 2026neutral

Edgewise Therapeutics announced that management will participate in two investor conferences: the Guggenheim Healthcare Innovation Conference on November 10, 2026, and the Truist Biopharma Symposium on November 12, 2026. Webcasts will be available on the company’s Events & Presentations page and for replay for a limited time.

Why it matters — EWTX watchers can follow management’s conference remarks through the scheduled webcasts and limited-time replays.

Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring

PRNewsWire · 5 Nov 2026positive

Edgewise reported favorable FDA feedback at its End-of-Phase 2 meeting for EDG-7500 in symptomatic obstructive and nonobstructive HCM. It submitted the STRATUS-HCM Phase 3 protocol, which uses investigator-assessed tolerability for dose escalation and is planned to start in Q4 2026.

Why it matters — The FDA feedback and submitted Phase 3 protocol outline the next clinical development step for EDG-7500 in both obstructive and nonobstructive HCM.

Edgewise Therapeutics Reports Third Quarter 2026 Financial Results

PRNewsWire · 4 Nov 2026positive

Edgewise Therapeutics reported third-quarter 2026 financial results and business updates, including publication of EDG-7500’s mechanism of action and plans to initiate its Phase 3 HCM trial by year-end. The company also dosed the first patient in the Phase 2 EQUINOX-HFpEF trial of EDG-15400.

Why it matters — The update gives EWTX watchers information on progress and timing for clinical trials across its cardiovascular programs.

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

PRNewsWire · 2 Nov 2026neutral

Edgewise Therapeutics granted inducement stock options covering 17,250 shares and restricted stock unit awards covering 8,626 shares to two new non-executive employees on October 30, 2026. The awards were made under the company's 2024 Inducement Equity Incentive Plan in connection with their employment.

Why it matters — The grants disclose equity compensation issued to new employees under the company's inducement plan.

Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400

PRNewsWire · 8 Oct 2026positive

Edgewise Therapeutics announced that the first patient has been dosed in EQUINOX-HFpEF, a Phase 2 trial of EDG-15400 in adults with symptomatic HFpEF and LVEF of at least 50%. The company said the trial design and Phase 1 first-in-human data are to be presented at HFSA 2026.

Why it matters — The dosing marks the start of a Phase 2 evaluation of EDG-15400 in the specified HFpEF population.

FAQ

Frequently asked questions about EWTX stock

What is the EWTX stock price forecast for 2026-2027?

The 13 Wall Street analysts covering Edgewise Therapeutics, Inc. have a median 12-month price target of $54, with estimates ranging from $36 to $85. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is EWTX stock a buy right now?

Of the 13 analysts covering Edgewise Therapeutics, Inc., 12 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Edgewise Therapeutics, Inc. 69 out of 100 across roughly 4,600 US stocks as at 16 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank EWTX?

As at 16 Nov 2026, Edgewise Therapeutics, Inc. ranks 69 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (92 of 100).

Will EWTX stock go up?

No one can know that. What the data says: the median 12-month target from 13 analysts implies +27.3% from the last close, and Ticker Nerd's factor model ranks Edgewise Therapeutics, Inc. 69 out of 100 as at 16 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the EWTX stock forecast for 2030?

No analyst covering Edgewise Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EWTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $36 to $85 over the next 12 months.

How has EWTX stock performed over the past year?

Edgewise Therapeutics, Inc. returned +88.9% over the 12 months to 17 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Edgewise Therapeutics, Inc. do?

Edgewise Therapeutics Inc. is a biopharmaceutical company focused on developing therapies for severe muscle and cardiac disorders.

What is the latest news on EWTX?

The most recent item we track (PRNewsWire, 9 Nov 2026): "Edgewise Therapeutics to Participate in Upcoming Investor Conferences". Edgewise Therapeutics announced that management will participate in two investor conferences: the Guggenheim Healthcare Innovation Conference on November 10, 2026, and the Truist Biopharma Symposium on November 12, 2026. Webcasts will be available on the company’s Events & Presentations page and for replay for a limited time.

Company

About Edgewise Therapeutics, Inc.

Edgewise Therapeutics Inc. is a biopharmaceutical company focused on developing therapies for severe muscle and cardiac disorders. The company’s current portfolio centers on precision medicine programs designed to address rare neuromuscular diseases and inherited heart conditions, with a platform built around small-molecule approaches that target key muscle proteins and pathways. Its work spans muscular dystrophy and hypertrophic cardiomyopathy research, as well as other disorders where abnormal muscle function plays a central role. Edgewise Therapeutics Inc. operates as a clinical-stage developer of medicines aimed at improving how muscle diseases are treated in specialized medical settings, supporting both neuromuscular and cardiovascular care.

CEO Dr. Kevin Koch Ph.D. · 133 employees · United States · https://edgewisetx.com